Home >> Signaling Pathways >> Tyrosine Kinase >> Bcr-Abl


Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

  1. Cat.No. Product Name Information
  2. A8812 PD173955 PD173955 is a potent inhibitor of Bcr-Abl, Src and Yes with IC50 value of 1-2 nM, 300 nM and 175 nM, respectively [1-3].
  3. A8607 PPY A Potent inhibitor of T315l mutant and wild-type Abl kinases (IC50 values are 9 and 20 nM, respectively).
  4. A8606 PD 180970 ATP-competitive inhibitor of p210bcr/abl tyrosine kinase; selectively induces apoptosis in chronic myeloid leukemia (CML) K562 cells.
  5. A8605 1-Naphthyl PP1 Selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl.
  6. A8604 GNF 5 GNF-5 is a potent, selective, non-ATP competitive allosteric inhibitor of Bcr-Abl with IC50 value of 220 nM.
  7. A8603 GNF 2 GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 100 to 300 nM in various cell lines.
  8. A8602 Adaphostin p210bcr/abl tyrosine kinase inhibitor (IC50 = 14 μM). Induces apoptosis in T-lymphoblastic human leukemia cell lines (IC50 values range from 16.8 to 216.3 nM) in vitro.
  9. A2133 Saracatinib (AZD0530) Saracatinib (AZD0530) is a novel, potent Src family kinase (SFK)/Abl dual-kinase inhibitor with IC50 value of 2.7 nM .
  10. A2149 Bosutinib (SKI-606) Bosutinib (SKI-606) is a potent inhibitor of Src and Abl kinases with IC50 of 1.2 nM and 1 nM .
  11. A3373 DPH DPH is c-ABL activitor.

Items 1 to 10 of 23 total

per page
  1. 1
  2. 2
  3. 3

Set Descending Direction